Cited 19 time in
Trends of thromboprophylaxis and complications after major lower limb orthopaedic surgeries in Korea: National Health Insurance Claim Data
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Kim, Sunyoung | - |
| dc.contributor.author | Ahn, Hongyup | - |
| dc.contributor.author | Shin, Soon-ae | - |
| dc.contributor.author | Park, Jong-heon | - |
| dc.contributor.author | Won, Chang Won | - |
| dc.date.accessioned | 2024-08-08T01:02:01Z | - |
| dc.date.available | 2024-08-08T01:02:01Z | - |
| dc.date.issued | 2017-07 | - |
| dc.identifier.issn | 0049-3848 | - |
| dc.identifier.uri | https://scholarworks.dongguk.edu/handle/sw.dongguk/14854 | - |
| dc.description.abstract | Background: In Western countries, prophylaxis for venous thromboembolism (VTE) following major lower limb orthopaedic surgeries is recommended. However, that has not been the case in Asian countries, where the reported incidence of postoperative VTE has been low. The present study examined trends in VTE prophylaxis prescriptions and related complications following major lower limb orthopaedic surgeries in South Korea. Design/Participants: Using claim data from the National Health Insurance Corporation, 263,664 patients aged 65 years or older who underwent major orthopaedic surgeries (total hip arthroplasty [THA], total knee arthroplasty [TKA], or hip fracture surgery [HFS]) between 2008 and 2012 were included. Result: The prescription rate for VTE prophylaxis has increased from 62.4% in 2008 to 75.4% in 2012 (P < 0.001). The prescription rate for new oral anticoagulants following THA and TKA has increased drastically since 2010, while that following HFS has not. Instead, prophylactic use of aspirin or low molecular weight heparin has increased in HFS cases. The rate of postoperative complications has significantly increased annually only in HFS: VTE (P = 0.018) and brain haemorrhage or gastrointestinal bleeding (P= 0.019). Conclusion: This result could suggest the need for more studies about the use of VTE prophylactic medicines following HFS. (C) 2017 Elsevier Ltd. All rights reserved. | - |
| dc.format.extent | 5 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | PERGAMON-ELSEVIER SCIENCE LTD | - |
| dc.title | Trends of thromboprophylaxis and complications after major lower limb orthopaedic surgeries in Korea: National Health Insurance Claim Data | - |
| dc.type | Article | - |
| dc.publisher.location | 영국 | - |
| dc.identifier.doi | 10.1016/j.thromres.2017.04.023 | - |
| dc.identifier.scopusid | 2-s2.0-85018309745 | - |
| dc.identifier.wosid | 000405681800010 | - |
| dc.identifier.bibliographicCitation | THROMBOSIS RESEARCH, v.155, pp 48 - 52 | - |
| dc.citation.title | THROMBOSIS RESEARCH | - |
| dc.citation.volume | 155 | - |
| dc.citation.startPage | 48 | - |
| dc.citation.endPage | 52 | - |
| dc.type.docType | Article | - |
| dc.description.isOpenAccess | N | - |
| dc.description.journalRegisteredClass | sci | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | Hematology | - |
| dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
| dc.relation.journalWebOfScienceCategory | Hematology | - |
| dc.relation.journalWebOfScienceCategory | Peripheral Vascular Disease | - |
| dc.subject.keywordPlus | DEEP VENOUS THROMBOSIS | - |
| dc.subject.keywordPlus | KNEE ARTHROPLASTY | - |
| dc.subject.keywordPlus | THROMBOEMBOLISM | - |
| dc.subject.keywordPlus | PREVENTION | - |
| dc.subject.keywordPlus | RISK | - |
| dc.subject.keywordPlus | GUIDELINES | - |
| dc.subject.keywordPlus | HIP | - |
| dc.subject.keywordPlus | RIVAROXABAN | - |
| dc.subject.keywordPlus | ENOXAPARIN | - |
| dc.subject.keywordAuthor | Anticoagulant drug | - |
| dc.subject.keywordAuthor | Guideline | - |
| dc.subject.keywordAuthor | Hip fracture | - |
| dc.subject.keywordAuthor | Haemorrhage | - |
| dc.subject.keywordAuthor | Venous thromboembolism | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
30, Pildong-ro 1-gil, Jung-gu, Seoul, 04620, Republic of Korea+82-2-2260-3114
Copyright(c) 2023 DONGGUK UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
